Morgan Stanley’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,539,826
| Closed | -$24.2M | – | 8011 |
|
|
2024
Q1 | $24.2M | Sell |
1,539,826
-3,093,040
| -67% | -$47.6M | ﹤0.01% | 2493 |
|
|
2023
Q4 | $74.7M | Buy |
4,632,866
+3,039,881
| +191% | +$38.8M | ﹤0.01% | 2023 |
|
|
2023
Q3 | $20.3M | Buy |
1,592,985
+222,276
| +16% | +$3.07M | ﹤0.01% | 2431 |
|
|
2023
Q2 | $19.3M | Buy |
1,370,709
+436,913
| +47% | +$6.25M | ﹤0.01% | 2514 |
|
|
2023
Q1 | $14.4M | Buy |
933,796
+324,538
| +53% | +$5.42M | ﹤0.01% | 2783 |
|
|
2022
Q4 | $9.99M | Buy |
609,258
+7,555
| +1% | +$123K | ﹤0.01% | 3097 |
|
|
2022
Q3 | $11.1M | Sell |
601,703
-305,493
| -34% | -$4.79M | ﹤0.01% | 2843 |
|
|
2022
Q2 | $11.9M | Buy |
907,196
+214,572
| +31% | +$2.37M | ﹤0.01% | 2883 |
|
|
2022
Q1 | $6.42M | Buy |
692,624
+459,504
| +197% | +$3.91M | ﹤0.01% | 3409 |
|
|
2021
Q4 | $2.28M | Buy |
233,120
+186,189
| +397% | +$3.5M | ﹤0.01% | 4476 |
|
|
2021
Q3 | $1.59M | Buy |
46,931
+2,799
| +6% | +$89.3K | ﹤0.01% | 4751 |
|
|
2021
Q2 | $1.61M | Buy |
44,132
+24,834
| +129% | +$962K | ﹤0.01% | 4793 |
|
|
2021
Q1 | $865K | Sell |
19,298
-19,367
| -50% | -$902K | ﹤0.01% | 4822 |
|
|
2020
Q4 | $2.21M | Buy |
38,665
+26,245
| +211% | +$1.56M | ﹤0.01% | 4064 |
|
|
2020
Q3 | $636K | Sell |
12,420
-83,399
| -87% | -$4.09M | ﹤0.01% | 4511 |
|
|
2020
Q2 | $5.72M | Buy |
95,819
+68,317
| +248% | +$3.65M | ﹤0.01% | 2537 |
|
|
2020
Q1 | $1.13M | Sell |
27,502
-10,787
| -28% | -$599K | ﹤0.01% | 3861 |
|
|
2019
Q4 | $2.38M | Sell |
38,289
-302,667
| -89% | -$14.4M | ﹤0.01% | 3898 |
|
|
2019
Q3 | $11.6M | Buy |
340,956
+333,092
| +4,236% | +$9.86M | ﹤0.01% | 1971 |
|
|
2019
Q2 | $177K | Buy |
7,864
+5,366
| +215% | +$126K | ﹤0.01% | 5073 |
|
|
2019
Q1 | $58K | Sell |
2,498
-40,601
| -94% | -$1.06M | ﹤0.01% | 5606 |
|
|
2018
Q4 | $904K | Buy |
43,099
+28,295
| +191% | +$696K | ﹤0.01% | 4352 |
|
|
2018
Q3 | $573K | Sell |
14,804
-2,680
| -15% | -$99K | ﹤0.01% | 4928 |
|
|
2018
Q2 | $688K | Buy |
17,484
+2,175
| +14% | +$64K | ﹤0.01% | 4881 |
|
|
2018
Q1 | $307K | Buy |
15,309
+911
| +6% | +$23.1K | ﹤0.01% | 5272 |
|
|
2017
Q4 | $326K | Buy |
+14,398
| New | +$282K | ﹤0.01% | 5209 |
|
Other funds holding DCPH
Morgan Stanley's DCPH Position: Q2 2024 in Review
Morgan Stanley sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,539,826 shares — an estimated $24.2M sold.
Morgan Stanley first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $74.7M in Q4 2023. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Morgan Stanley reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Morgan Stanley sold 1,539,826 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $24.2M.
- Morgan Stanley first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
- Morgan Stanley's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $74.7M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.